-
Turnstone Biologics Corp (TSBX) Presents Preclinical Data Highlighting Potential for Selected Tumor-Infiltrating Lymphocyte Therapy
-
BofA Securities Downgrades Turnstone Biologics (TSBX) to Neutral
-
Turnstone Biologics Corp (TSBX) Announces Strategic Restructuring
-
Turnstone Biologics (TSBX) PT Lowered to $3.75 at Piper Sandler
-
Turnstone Biologics Corp (TSBX) Reports Positive Initial Data from Phase 1 Trial of TIDAL-01 in Metastatic Colorectal Cancer

